IL276623A - Dosing regimens of B7-H4 antibody - Google Patents

Dosing regimens of B7-H4 antibody

Info

Publication number
IL276623A
IL276623A IL276623A IL27662320A IL276623A IL 276623 A IL276623 A IL 276623A IL 276623 A IL276623 A IL 276623A IL 27662320 A IL27662320 A IL 27662320A IL 276623 A IL276623 A IL 276623A
Authority
IL
Israel
Prior art keywords
dosing regimens
antibody dosing
antibody
regimens
dosing
Prior art date
Application number
IL276623A
Other languages
English (en)
Hebrew (he)
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of IL276623A publication Critical patent/IL276623A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL276623A 2018-02-21 2020-08-10 Dosing regimens of B7-H4 antibody IL276623A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862633527P 2018-02-21 2018-02-21
US201962802100P 2019-02-06 2019-02-06
PCT/US2019/018963 WO2019165075A1 (en) 2018-02-21 2019-02-21 B7-h4 antibody dosing regimens

Publications (1)

Publication Number Publication Date
IL276623A true IL276623A (en) 2020-09-30

Family

ID=65686103

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276623A IL276623A (en) 2018-02-21 2020-08-10 Dosing regimens of B7-H4 antibody

Country Status (12)

Country Link
US (3) US20210070862A1 (cg-RX-API-DMAC7.html)
EP (1) EP3755719A1 (cg-RX-API-DMAC7.html)
JP (2) JP7258038B6 (cg-RX-API-DMAC7.html)
KR (1) KR102863169B1 (cg-RX-API-DMAC7.html)
CN (1) CN111868089B (cg-RX-API-DMAC7.html)
AU (1) AU2019226009B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016990A2 (cg-RX-API-DMAC7.html)
IL (1) IL276623A (cg-RX-API-DMAC7.html)
MA (1) MA51902A (cg-RX-API-DMAC7.html)
MX (1) MX2020008730A (cg-RX-API-DMAC7.html)
SG (1) SG11202007820QA (cg-RX-API-DMAC7.html)
WO (1) WO2019165075A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
WO2019165077A1 (en) * 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
AU2019361923B2 (en) * 2018-10-15 2026-07-09 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2022147532A1 (en) 2021-01-04 2022-07-07 Mersana Therapeutics, Inc. B7h4-targeted antibody-drug conjugates and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
CA2923247A1 (en) 2002-03-19 2003-09-25 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
US9676854B2 (en) * 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
AU2013361275B2 (en) * 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
MX374785B (es) 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
CN107299085B (zh) * 2017-05-26 2020-09-29 广东医科大学 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
WO2019165077A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations

Also Published As

Publication number Publication date
US20240317864A1 (en) 2024-09-26
JP7258038B2 (ja) 2023-04-14
BR112020016990A2 (pt) 2021-02-23
EP3755719A1 (en) 2020-12-30
CN111868089A (zh) 2020-10-30
WO2019165075A1 (en) 2019-08-29
MX2020008730A (es) 2020-12-07
MA51902A (fr) 2021-05-26
KR102863169B1 (ko) 2025-09-22
JP2023089063A (ja) 2023-06-27
AU2019226009B2 (en) 2025-11-20
CN111868089B (zh) 2025-08-22
US20210070862A1 (en) 2021-03-11
JP7258038B6 (ja) 2023-04-25
SG11202007820QA (en) 2020-09-29
JP2021513997A (ja) 2021-06-03
AU2019226009A1 (en) 2020-09-03
US20230287123A1 (en) 2023-09-14
CA3091161A1 (en) 2019-08-29
KR20200123169A (ko) 2020-10-28

Similar Documents

Publication Publication Date Title
IL279321A (en) Anti-SIRPalpha antibody
IL280780A (en) Anti-TIGIT antibodies
IL283812A (en) Humanized antibody against human pd–1
IL280013A (en) Anti-IL36R antibodies
IL279352A (en) IL-11RA antibodies
IL278010A (en) Antibodies to galectin 10
GB201817172D0 (en) Antibody
IL282756A (en) Humanized antibodies against SIRPα
IL277030A (en) Antibodies
IL276626A (en) Formulations of B7-H4 antibody
SG11202106171WA (en) Anti-btla antibodies
SG11202007820QA (en) B7-h4 antibody dosing regimens
ZA202101177B (en) Anti-btla antibody
GB201811368D0 (en) Antibody
SG11202102114UA (en) Anti-klrg1 antibodies
GB201911211D0 (en) Monoclonal antibodies against ambra-1
GB201820006D0 (en) Humanised anti-IL17BR antibody
GB201806084D0 (en) Antibodies
IL280515A (en) Dosing regimens for elagolix
GB201815549D0 (en) Arginase1 polypeptides
GB201910138D0 (en) Anti-pd-l1 antibodies
HK40041710A (en) B7-h4 antibody dosing regimens
EP3703728A4 (en) DOSING SCHEMES FOR COELIAKIA
GB201511196D0 (en) Monoclonal antibodies
HK40054775A (en) Dosing regimens for elagolix